FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095162893> ?p ?o ?g. }

• W2095162893 endingPage "112" @default.
• W2095162893 startingPage "104" @default.
• W2095162893 abstract "Abstract The safety, pharmacokinetics, and antitumor activity of the multikinase inhibitor regorafenib in Japanese patients was assessed in this multicenter, single-arm, phase I trial. Fifteen patients with treatment-refractory advanced solid tumors received regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle until disease progression, unacceptable toxicity, or investigator or patient decision to stop. The median duration of treatment was 2.1 months (range, 0.9–20.1 months). At data cutoff, one patient was still receiving regorafenib in cycle 21. Reasons for treatment discontinuation were disease progression ( n = 12) and adverse events (liver enzyme elevation n = 1; anemia n = 1). Adverse events necessitated dose reduction in six patients, interruption of daily treatment in seven patients, and cycle delay in four patients. All patients experienced at least one drug-related adverse event, particularly gastrointestinal (87 %), dermatologic (73 %), or hematologic (67 %) events. There was no significant change in time to maximum concentration or terminal half-life of regorafenib and its active metabolites M2 and M5 between single dosing and 21-day continuous dosing. The area under the concentration–time curve was 2.1-fold higher for regorafenib, 5.2-fold higher for M2, and 37.3-fold higher for M5, and the maximum concentration was 2.0-fold, 4.8-fold, and 36.0-fold higher, respectively, after continuous dosing than after single dosing. One patient had a partial response (duration 10.5 months) and seven patients had stable disease. This study indicates that regorafenib 160 mg orally once daily (21 days on/7 days off treatment) can be given to Japanese patients who have solid tumors, without undue toxicity." @default.
• W2095162893 created "2016-06-24" @default.
• W2095162893 creator A5013994958 @default.
• W2095162893 creator A5021407007 @default.
• W2095162893 creator A5022537134 @default.
• W2095162893 creator A5033256310 @default.
• W2095162893 creator A5034993620 @default.
• W2095162893 creator A5052078893 @default.
• W2095162893 creator A5054771200 @default.
• W2095162893 creator A5056197140 @default.
• W2095162893 creator A5076349434 @default.
• W2095162893 creator A5076696174 @default.
• W2095162893 date "2013-04-04" @default.
• W2095162893 modified "2023-09-24" @default.
• W2095162893 title "Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics" @default.
• W2095162893 cites W1968209756 @default.
• W2095162893 cites W1996160829 @default.
• W2095162893 cites W2012708129 @default.
• W2095162893 cites W2062174133 @default.
• W2095162893 cites W2067216473 @default.
• W2095162893 cites W2075446367 @default.
• W2095162893 cites W2081071240 @default.
• W2095162893 cites W2116922255 @default.
• W2095162893 cites W2125763124 @default.
• W2095162893 cites W2147834058 @default.
• W2095162893 doi "https://doi.org/10.1007/s10637-013-9953-8" @default.
• W2095162893 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4079679" @default.
• W2095162893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23553067" @default.
• W2095162893 hasPublicationYear "2013" @default.
• W2095162893 type Work @default.
• W2095162893 sameAs 2095162893 @default.
• W2095162893 citedByCount "46" @default.
• W2095162893 countsByYear W20951628932014 @default.
• W2095162893 countsByYear W20951628932015 @default.
• W2095162893 countsByYear W20951628932016 @default.
• W2095162893 countsByYear W20951628932017 @default.
• W2095162893 countsByYear W20951628932018 @default.
• W2095162893 countsByYear W20951628932019 @default.
• W2095162893 countsByYear W20951628932020 @default.
• W2095162893 countsByYear W20951628932021 @default.
• W2095162893 countsByYear W20951628932022 @default.
• W2095162893 crossrefType "journal-article" @default.
• W2095162893 hasAuthorship W2095162893A5013994958 @default.
• W2095162893 hasAuthorship W2095162893A5021407007 @default.
• W2095162893 hasAuthorship W2095162893A5022537134 @default.
• W2095162893 hasAuthorship W2095162893A5033256310 @default.
• W2095162893 hasAuthorship W2095162893A5034993620 @default.
• W2095162893 hasAuthorship W2095162893A5052078893 @default.
• W2095162893 hasAuthorship W2095162893A5054771200 @default.
• W2095162893 hasAuthorship W2095162893A5056197140 @default.
• W2095162893 hasAuthorship W2095162893A5076349434 @default.
• W2095162893 hasAuthorship W2095162893A5076696174 @default.
• W2095162893 hasBestOaLocation W20951628931 @default.
• W2095162893 hasConcept C112705442 @default.
• W2095162893 hasConcept C121332964 @default.
• W2095162893 hasConcept C121608353 @default.
• W2095162893 hasConcept C126322002 @default.
• W2095162893 hasConcept C142424586 @default.
• W2095162893 hasConcept C197934379 @default.
• W2095162893 hasConcept C2776248978 @default.
• W2095162893 hasConcept C2777288759 @default.
• W2095162893 hasConcept C2778248108 @default.
• W2095162893 hasConcept C2778715236 @default.
• W2095162893 hasConcept C29730261 @default.
• W2095162893 hasConcept C526805850 @default.
• W2095162893 hasConcept C71924100 @default.
• W2095162893 hasConcept C87355193 @default.
• W2095162893 hasConcept C90924648 @default.
• W2095162893 hasConcept C98274493 @default.
• W2095162893 hasConceptScore W2095162893C112705442 @default.
• W2095162893 hasConceptScore W2095162893C121332964 @default.
• W2095162893 hasConceptScore W2095162893C121608353 @default.
• W2095162893 hasConceptScore W2095162893C126322002 @default.
• W2095162893 hasConceptScore W2095162893C142424586 @default.
• W2095162893 hasConceptScore W2095162893C197934379 @default.
• W2095162893 hasConceptScore W2095162893C2776248978 @default.
• W2095162893 hasConceptScore W2095162893C2777288759 @default.
• W2095162893 hasConceptScore W2095162893C2778248108 @default.
• W2095162893 hasConceptScore W2095162893C2778715236 @default.
• W2095162893 hasConceptScore W2095162893C29730261 @default.
• W2095162893 hasConceptScore W2095162893C526805850 @default.
• W2095162893 hasConceptScore W2095162893C71924100 @default.
• W2095162893 hasConceptScore W2095162893C87355193 @default.
• W2095162893 hasConceptScore W2095162893C90924648 @default.
• W2095162893 hasConceptScore W2095162893C98274493 @default.
• W2095162893 hasIssue "1" @default.
• W2095162893 hasLocation W20951628931 @default.
• W2095162893 hasLocation W20951628932 @default.
• W2095162893 hasLocation W20951628933 @default.
• W2095162893 hasLocation W20951628934 @default.
• W2095162893 hasOpenAccess W2095162893 @default.
• W2095162893 hasPrimaryLocation W20951628931 @default.
• W2095162893 hasRelatedWork W2004325424 @default.
• W2095162893 hasRelatedWork W2051764329 @default.
• W2095162893 hasRelatedWork W2095162893 @default.
• W2095162893 hasRelatedWork W2116572758 @default.
• W2095162893 hasRelatedWork W2351796763 @default.
• W2095162893 hasRelatedWork W2774225352 @default.

• next